Liver Diseases, Alcoholic, Fibrosis
Conditions
Keywords
elastography, screening, non-invasive markers, microbiome, gut-liver-axis, cost-benefit, fibroscan, aixplorer, ultrasound elastography, liver fibrosis, alcoholic liver disease, advanced fibrosis, enhanced liver fibrosis test, direct liver fibrosis markers, ELF, cytokeratin-18, neoepitopes, collagen, NAFLD, ALD, metabolomics, non-alcoholic fatty liver disease
Brief summary
Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.
Detailed description
This protocol describes a prospective screening study at Odense University Hospital, Department of Gastroenterology and Hepatology. The investigators will use liver stiffness measurements with transient elastography to screen 3000 participants from at-risk populations and 3500 participants from the general population for advanced liver fibrosis. At-risk is defined as either (A) a prior or current alcohol overuse (≥21 units/week for men and ≥14 units/week for women) for more than 5 years, or (B) presence of the metabolic syndrome with or without concomitant type 2 diabetes mellitus. The study goal is to evaluate the aptitude of transient elastography as a screening tool for advanced liver fibrosis, based on analyses of benefit, harm, detection rate, technical applicability and prognostic potential. Secondary aims are to compare novel serum markers of liver fibrosis as potential screening tools against transient elastography: The Enhanced Liver Fibrosis test, neoepitope markers of extracellular matrix turnover, cytokeratin-18 based markers and indirect indices of fibrosis from algorithms combining routine liver blood test. Screened participants with elevated liver stiffness (≥8.0 kiloPascal; estimated 400 participants with alcoholic liver disease, 400 participants with non-alcoholic fatty liver disease and 280 participants from the general population) will be investigated with 2-dimensional shear-wave elastography and abdominal ultrasonography and a liver biopsy to confirm or reject presence of advanced fibrosis. All participants with a positive screening elastography will be invited for repeated liver stiffness measurements and serum fibrosis markers after a minimum of one year from inclusion. Participants at risk of alcoholic and non-alcoholic liver disease, independent of liver stiffness measurement at inclusion, will be invited for repeated liver stiffness measurements and serum fibrosis markers after a minimum of one year from inclusion. At-risk participants with elevated liver stiffness measurements at a follow-up visit (\>6.0 kiloPascal) will be offered a liver biopsy, however no earlier than two years after the index biopsy. All participants will be followed for 10 years to assess liver-related outcomes and all-course mortality.
Interventions
DIAGNOSTIC_TESTtransient elastography
Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
DIAGNOSTIC_TESTEnhanced liver fibrosis test
Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
DIAGNOSTIC_TESTIndirect serum markers of liver fibrosis
Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
DIAGNOSTIC_TESTDirect serum markers of liver fibrosis
Serum markers that reflect liver extracellular matrix turnover and -accumulation
DIAGNOSTIC_TESTLiverTRAIL
Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
DIAGNOSTIC_TESTCytokeratin 18
Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
DIAGNOSTIC_TESTOmics markers
Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
Sponsors
Horizon 2020 - European Commission
Novo Nordisk A/S
University of Southern Denmark
Esbjerg University Hospital of South-West Jutland
Odense Municipality Alcohol Rehabilitation Unit
Svendborg Municipality Alcohol Rehabilitation Unit
University of Copenhagen
University of Oslo
Nordic Bioscience A/S
VLV Bio, Peviva AB
Manatee APS
Siemens Healthcare A/S
Steno Diabetes Center Copenhagen
Biomedical Research Foundation, Academy of Athens
European Molecular Biology Laboratory, EMBL, University of Heidelberg
Maja Thiele
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Single intervention group selected for screening with a historical control group
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patients are eligible for screening if the following inclusion criteria are fulfilled: * Age 30-75 years (except the general population, which should be aged 40-75) * Informed consent to study investigations * Ability to read and write Danish AND (only at-risk patients) * Prior or current alcohol overuse, defined as an average intake of ≥24 grams/day (14 units/week) for women and ≥36 grams/day (21 units/week) for men, for at least 5 years; OR * Presence of the metabolic syndrome defined by central obesity plus any two of the following four metabolic risk factors: (a) raised triglycerides, (b) reduced HDL cholesterol, (c) raised blood pressure and (d) raised fasting plasma glucose;\[38\] OR * Type 2 diabetes mellitus defined by either fasting plasma glucose ≥7 mmol/L, HbA1c ≥48 mmol/mol, a random plasma glucose ≥11.1 mmol/L in the presence of classic diabetes or an oral glucose tolerance test with fasting plasma glucose ≥7.0 mmol/L and/or 2 hour plasma glucose ≥11.1 mmol/L.
Exclusion criteria
We will exclude patients from screening in case of: * Evidence of decompensated liver disease, defined by clinically obvious ascites, overt hepatic encephalopathy, jaundice or large esophageal varices with/without variceal bleeding. * Known concurrent liver disease other than ALD and NAFLD. * Cancer or other debilitating disease with an expected survival of less than 12 months. * Inability to comply with the study protocol. In screened patients with liver stiffness ≥8 kPa we will abstain from a liver biopsy in case of: * Contraindications for a percutaneous liver biopsy * Severe alcoholic hepatitis or other hepatic inflammation evidenced by transaminase elevation of more than three times the upper limit of normal. * Hepatic congestion or bile duct dilation evidenced by ultrasound. * Decrease of TE below 6.0 kPa from screening to time of planned liver biopsy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biopsy-verified advanced fibrosis | 5 years | Number of patients with biopsy-verified, advanced fibrosis (Kleiner fibrosis score ≥F3) detected by screening |
| Liver-related outcomes | 10 years | Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score \>15 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Liver related outcomes | 10 years | Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score \>15 |
| Mortality | 10 years | Overall number of deaths during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). |
Countries
Denmark
Contacts
Primary ContactMaja Thiele, MD, PhD, Professor
Outcome results
None listed